Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

[JLS1]

Impressive!:

Case presentation

Here, we report on two patients who received ipilimumab in these trials and are still in long-term complete remission with a follow-up of 64 and 52 months respectively after the initiation of ipilimumab. Immunohistochemical staining for hMLH1, hMSH2, hMSH6 and PMS2 was performed on archival prostate biopsy samples from one of the two patients; they exhibited normal protein expression. Interestingly for this patient, a high CD3+ and CD8+ T cell infiltration was observed on archival prostate biopsies as well as Treg FoxP3+ T cells.

Conclusion

Ipilimumab produces clinical activity in patients with CRPC, including very long responders with no detectable residual disease.

Full story:

jitc.biomedcentral.com/arti...

Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Luc CabelEmail author, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi

Journal for ImmunoTherapy of Cancer20175:31

doi.org/10.1186/s40425-017-...

© The Author(s). 2017

Received: 4 January 2017

Accepted: 14 March 2017

Published: 18 April 2017

[tango65]

Very interesting.

[Frank_M]

There have been several large randomised controlled trials of Ipilimumab in prostate cancer which showed no benefit on overall survival. Google: Ipilimumab prostate.

[Hidden in reply to Frank_M]

You are correct. In one trial, the placebo group had better OS. "Among the 399 treated with ipilimumab and the 199 given placebo, median overall survival was 28.7 months and 29.7 months, respectively."

[Dan59]

I remember 10 years ago Dr. Sholtz being very excited by Ipilimumab and other drugs that target CTLA4, apparently for who it worked it worked very well. Just to show we never know what is going to work very well for who. Thanks for posting these case studies, it gives great hope.

Dan

[paulofaus]

It always amazes me how a very small number get an incredible response to some of these agents and most get little if any. I read somewhere that they have identified 24 sub-types of prostate cancer, so we need better testing to find out which strain we have so the treatments can be targeted. I asked my MO about it the other day and she wasn't any help.

[Hidden]

It's got to be pretty bad when you test hundereds of people and the placebo has better overall survival. How does it get any worse than that?